Global Hypereosinophilic Syndrome Drug Market
Global Hypereosinophilic Syndrome Drug Market

Hypereosinophilic Syndrome Drug Comprehensive Study by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), Application (Research Center, Hospital, Clinic) Players and Region - Global Market Outlook to 2026

Hypereosinophilic Syndrome Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 246 Pages 162 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Hypereosinophilic Syndrome Drug Market Overview:
The hypereosinophilic syndrome drug market is expected to grow due to increased knowledge of the disease, increased investments by major players globally, increased government initiatives, and a robust product pipeline. Hypereosinophilic syndrome (HES) is characterized by a high eosinophil count in the blood. Eosinophils are a type of white blood cell that plays a critical role in the immune system.

Growth Drivers
  • Increased Prevalence of Hypereosinophilic Syndrome
  • Rising Number of Diagnostic Centres

Market Trends
  • Surging Recommendation of the Drug from the Doctor

Roadblocks
  • Lack of Knowledge about Hypereosinophilic Syndrome

Opportunities
  • Increased Research and Development Investments
  • Growth in Developing Countries

Challenges
  • Stringent Government Rules and Regulations


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb Company (United States), Kyowa Hakko Kirin Co., Ltd. (Japan), Knopp Biosciences LLC (United States), Stemline Therapeutics, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (United States) and AstraZeneca plc (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Hypereosinophilic Syndrome Drug market by 2026.

In September 2020, GlaxoSmithKline plc (GSK) announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.

What Can be Explored with the Hypereosinophilic Syndrome Drug Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hypereosinophilic Syndrome Drug Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hypereosinophilic Syndrome Drug
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hypereosinophilic Syndrome Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hypereosinophilic Syndrome Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Hypereosinophilic Syndrome Drug Manufacturers, Research Organizations and Consulting Companies, New Entrants/Investors, Analysts and Strategic Business Planners, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Benralizumab
  • Dasatinib
  • Dexpramipexole Dihydrochloride
  • Mepolizumab
  • Others
By Application
  • Research Center
  • Hospital
  • Clinic
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hypereosinophilic Syndrome
      • 3.2.2. Rising Number of Diagnostic Centres
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Surging Recommendation of the Drug from the Doctor
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hypereosinophilic Syndrome Drug, by Type, Application and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hypereosinophilic Syndrome Drug (Value)
      • 5.2.1. Global Hypereosinophilic Syndrome Drug by: Type (Value)
        • 5.2.1.1. Benralizumab
        • 5.2.1.2. Dasatinib
        • 5.2.1.3. Dexpramipexole Dihydrochloride
        • 5.2.1.4. Mepolizumab
        • 5.2.1.5. Others
      • 5.2.2. Global Hypereosinophilic Syndrome Drug by: Application (Value)
        • 5.2.2.1. Research Center
        • 5.2.2.2. Hospital
        • 5.2.2.3. Clinic
      • 5.2.3. Global Hypereosinophilic Syndrome Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Hypereosinophilic Syndrome Drug (Price)
      • 5.3.1. Global Hypereosinophilic Syndrome Drug by: Type (Price)
  • 6. Hypereosinophilic Syndrome Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Kyowa Hakko Kirin Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Knopp Biosciences LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Stemline Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hypereosinophilic Syndrome Drug Sale, by Type, Application and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hypereosinophilic Syndrome Drug (Value)
      • 7.2.1. Global Hypereosinophilic Syndrome Drug by: Type (Value)
        • 7.2.1.1. Benralizumab
        • 7.2.1.2. Dasatinib
        • 7.2.1.3. Dexpramipexole Dihydrochloride
        • 7.2.1.4. Mepolizumab
        • 7.2.1.5. Others
      • 7.2.2. Global Hypereosinophilic Syndrome Drug by: Application (Value)
        • 7.2.2.1. Research Center
        • 7.2.2.2. Hospital
        • 7.2.2.3. Clinic
      • 7.2.3. Global Hypereosinophilic Syndrome Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Hypereosinophilic Syndrome Drug (Price)
      • 7.3.1. Global Hypereosinophilic Syndrome Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hypereosinophilic Syndrome Drug: by Type(USD Million)
  • Table 2. Hypereosinophilic Syndrome Drug Benralizumab , by Region USD Million (2015-2020)
  • Table 3. Hypereosinophilic Syndrome Drug Dasatinib , by Region USD Million (2015-2020)
  • Table 4. Hypereosinophilic Syndrome Drug Dexpramipexole Dihydrochloride , by Region USD Million (2015-2020)
  • Table 5. Hypereosinophilic Syndrome Drug Mepolizumab , by Region USD Million (2015-2020)
  • Table 6. Hypereosinophilic Syndrome Drug Others , by Region USD Million (2015-2020)
  • Table 7. Hypereosinophilic Syndrome Drug: by Application(USD Million)
  • Table 8. Hypereosinophilic Syndrome Drug Research Center , by Region USD Million (2015-2020)
  • Table 9. Hypereosinophilic Syndrome Drug Hospital , by Region USD Million (2015-2020)
  • Table 10. Hypereosinophilic Syndrome Drug Clinic , by Region USD Million (2015-2020)
  • Table 11. South America Hypereosinophilic Syndrome Drug, by Country USD Million (2015-2020)
  • Table 12. South America Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 13. South America Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 14. Brazil Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 15. Brazil Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 16. Argentina Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 17. Argentina Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 19. Rest of South America Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 20. Asia Pacific Hypereosinophilic Syndrome Drug, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 22. Asia Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 23. China Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 24. China Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 25. Japan Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 26. Japan Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 27. India Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 28. India Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 29. South Korea Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 30. South Korea Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 31. Taiwan Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 32. Taiwan Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 33. Australia Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 34. Australia Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 37. Europe Hypereosinophilic Syndrome Drug, by Country USD Million (2015-2020)
  • Table 38. Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 39. Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 40. Germany Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 41. Germany Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 42. France Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 43. France Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 44. Italy Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 45. Italy Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 47. United Kingdom Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 48. Netherlands Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 49. Netherlands Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 51. Rest of Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 52. MEA Hypereosinophilic Syndrome Drug, by Country USD Million (2015-2020)
  • Table 53. MEA Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 54. MEA Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 55. Middle East Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 56. Middle East Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 57. Africa Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 58. Africa Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 59. North America Hypereosinophilic Syndrome Drug, by Country USD Million (2015-2020)
  • Table 60. North America Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 61. North America Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 62. United States Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 63. United States Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 64. Canada Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 65. Canada Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 66. Mexico Hypereosinophilic Syndrome Drug, by Type USD Million (2015-2020)
  • Table 67. Mexico Hypereosinophilic Syndrome Drug, by Application USD Million (2015-2020)
  • Table 68. Hypereosinophilic Syndrome Drug: by Type(USD/Units)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Hypereosinophilic Syndrome Drug: by Type(USD Million)
  • Table 80. Hypereosinophilic Syndrome Drug Benralizumab , by Region USD Million (2021-2026)
  • Table 81. Hypereosinophilic Syndrome Drug Dasatinib , by Region USD Million (2021-2026)
  • Table 82. Hypereosinophilic Syndrome Drug Dexpramipexole Dihydrochloride , by Region USD Million (2021-2026)
  • Table 83. Hypereosinophilic Syndrome Drug Mepolizumab , by Region USD Million (2021-2026)
  • Table 84. Hypereosinophilic Syndrome Drug Others , by Region USD Million (2021-2026)
  • Table 85. Hypereosinophilic Syndrome Drug: by Application(USD Million)
  • Table 86. Hypereosinophilic Syndrome Drug Research Center , by Region USD Million (2021-2026)
  • Table 87. Hypereosinophilic Syndrome Drug Hospital , by Region USD Million (2021-2026)
  • Table 88. Hypereosinophilic Syndrome Drug Clinic , by Region USD Million (2021-2026)
  • Table 89. South America Hypereosinophilic Syndrome Drug, by Country USD Million (2021-2026)
  • Table 90. South America Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 91. South America Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 92. Brazil Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 93. Brazil Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 94. Argentina Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 95. Argentina Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 96. Rest of South America Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 97. Rest of South America Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 98. Asia Pacific Hypereosinophilic Syndrome Drug, by Country USD Million (2021-2026)
  • Table 99. Asia Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 100. Asia Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 101. China Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 102. China Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 103. Japan Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 104. Japan Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 105. India Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 106. India Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 107. South Korea Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 108. South Korea Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 109. Taiwan Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 110. Taiwan Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 111. Australia Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 112. Australia Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 113. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 114. Rest of Asia-Pacific Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 115. Europe Hypereosinophilic Syndrome Drug, by Country USD Million (2021-2026)
  • Table 116. Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 117. Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 118. Germany Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 119. Germany Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 120. France Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 121. France Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 122. Italy Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 123. Italy Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 124. United Kingdom Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 125. United Kingdom Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 126. Netherlands Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 127. Netherlands Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 128. Rest of Europe Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 129. Rest of Europe Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 130. MEA Hypereosinophilic Syndrome Drug, by Country USD Million (2021-2026)
  • Table 131. MEA Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 132. MEA Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 133. Middle East Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 134. Middle East Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 135. Africa Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 136. Africa Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 137. North America Hypereosinophilic Syndrome Drug, by Country USD Million (2021-2026)
  • Table 138. North America Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 139. North America Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 140. United States Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 141. United States Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 142. Canada Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 143. Canada Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 144. Mexico Hypereosinophilic Syndrome Drug, by Type USD Million (2021-2026)
  • Table 145. Mexico Hypereosinophilic Syndrome Drug, by Application USD Million (2021-2026)
  • Table 146. Hypereosinophilic Syndrome Drug: by Type(USD/Units)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hypereosinophilic Syndrome Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Hypereosinophilic Syndrome Drug: by Application USD Million (2015-2020)
  • Figure 6. South America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 7. Asia Pacific Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 8. Europe Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 9. MEA Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 10. North America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 11. Global Hypereosinophilic Syndrome Drug: by Type USD/Units (2015-2020)
  • Figure 12. Global Hypereosinophilic Syndrome Drug share by Players 2020 (%)
  • Figure 13. Global Hypereosinophilic Syndrome Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Hypereosinophilic Syndrome Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 20. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 22. Knopp Biosciences LLC (United States) Revenue, Net Income and Gross profit
  • Figure 23. Knopp Biosciences LLC (United States) Revenue: by Geography 2020
  • Figure 24. Stemline Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Stemline Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 32. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Global Hypereosinophilic Syndrome Drug: by Type USD Million (2021-2026)
  • Figure 37. Global Hypereosinophilic Syndrome Drug: by Application USD Million (2021-2026)
  • Figure 38. South America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 39. Asia Pacific Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 40. Europe Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 41. MEA Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 42. North America Hypereosinophilic Syndrome Drug Share (%), by Country
  • Figure 43. Global Hypereosinophilic Syndrome Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc (United Kingdom)
  • Bristol-Myers Squibb Company (United States)
  • Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Knopp Biosciences LLC (United States)
  • Stemline Therapeutics, Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Novartis International AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Pfizer Inc (United States)
  • AstraZeneca plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation